Generic Oral Solid Dosage Forms – Cardiovascular Markets


  Generic Oral Solid Dosage Forms • GSD9F4K • August 2021 • US$1,850


 

 

The generic solid dosage form drug segment is a rapidly evolving and highly unpredictable environment that has been a challenge to decision makers attempting to map strategies for success in this segment. There are 597 distinct APIs for which there is at least one approved generic solid dosage form ANDA. These 597 APIs account for 4,229 approved ANDAs. Including all approved doses, the current universe of generic solid dosage forms consists of 9,687 unique tablet and capsule products. These products are marketed and supplied by more than 800 companies. Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.

sustained release injectables to 2028

 

 
 
 
 
     
 
 

 

What You Will Learn

  • Provides detailed analysis of generic drugs supplied as solid dosage forms and assesses key market segments, market dynamics and potential product opportunities
  • Presents the competitive picture for generic tablets and capsules in two dozen drug classes
  • Evaluates the importance of ANDA filing strategies and indirect ANDA acquisition on participant growth prospects
  • Analyzes the impact of patents, exclusivity and litigation on participant market sector prospects
  • Assesses the market presence and product position of the top twenty-four generic suppliers in the solid dosage form segment
  • Evaluates the impact of economic, technology, and regulatory factors

 

 

Generic Oral Solid Dosage Forms – Summary of Contents 

 

The Market Opportunity

 

The Economics of Generic Drugs

Growth in Generics

Demand Drivers

Competitive Landscape

 

Generic Solid Dosage Forms – Growth Factors

 

Generic SDFs – Product Considerations

 

Generic Solid Dosage Forms – Market Analysis

 

Therapeutic Class Analysis

Drug Classes

Indications

 

Market Factors

Regulatory Issues

Litigation Issues

Evolving ANDA Filing Strategies

The Role of CMOs

Healthcare Economics

 

Company Analysis